224 related articles for article (PubMed ID: 30535292)
1. Refractory Pyoderma Gangrenosum in a Patient With Crohn's Disease: Complete Response to Ustekinumab.
Nunes G; Patita M; Fernandes V
J Crohns Colitis; 2019 May; 13(6):812-813. PubMed ID: 30535292
[No Abstract] [Full Text] [Related]
2. Ustekinumab in a patient with pyoderma gangrenosum and refractory Crohn's disease.
García Cámara P; Zubiri Ara ML; García López S
Med Clin (Barc); 2019 Oct; 153(8):e35-e36. PubMed ID: 30795905
[No Abstract] [Full Text] [Related]
3. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study.
de Risi-Pugliese T; Seksik P; Bouaziz JD; Chasset F; Moguelet P; Gornet JM; Bourrier A; Amiot A; Beaugerie L; Francès C; Guégan S;
J Am Acad Dermatol; 2019 Mar; 80(3):781-784. PubMed ID: 30003991
[No Abstract] [Full Text] [Related]
4. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
5. Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn's disease.
Teich N
Tech Coloproctol; 2014 Oct; 18(10):965-6. PubMed ID: 24965074
[No Abstract] [Full Text] [Related]
6. Pyoderma gangrenosum solved by ustekinumab therapy.
López González J; Lázaro Sáez M; Moreno Moraleda I; Hernández Martínez Á
Gastroenterol Hepatol; 2021 Apr; 44(4):299-300. PubMed ID: 33069432
[No Abstract] [Full Text] [Related]
7. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab.
Low ZM; Mar A
Australas J Dermatol; 2018 May; 59(2):131-134. PubMed ID: 29205260
[TBL] [Abstract][Full Text] [Related]
8. Pyoderma Gangrenosum With Ulcerative Colitis Successfully Treated With Ustekinumab.
Piqueras-García J; Sahuquillo-Torralba AJ; Torres-Navarro I; Botella-Estrada R
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):776-778. PubMed ID: 31151671
[No Abstract] [Full Text] [Related]
9. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.
Grange F; Djilali-Bouzina F; Weiss AM; Polette A; Guillaume JC
Dermatology; 2002; 205(3):278-80. PubMed ID: 12399677
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review.
Nieto D; Sendagorta E; Rueda JM; Herranz P
Clin Exp Dermatol; 2019 Jan; 44(1):116-119. PubMed ID: 29851121
[No Abstract] [Full Text] [Related]
11. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab.
Benzaquen M; Monnier J; Beaussault Y; Rouby F; Berbis P
Australas J Dermatol; 2017 Nov; 58(4):e270-e271. PubMed ID: 28660635
[No Abstract] [Full Text] [Related]
12. Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma.
Cosgarea I; Lovric Z; Körber A; Dissemond J
Int Wound J; 2016 Oct; 13(5):1041-2. PubMed ID: 25294697
[No Abstract] [Full Text] [Related]
13. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.
Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U
J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
Cocco A; Angelucci E; Viscido A; Caprilli R
Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
[No Abstract] [Full Text] [Related]
15. Refractory, disfiguring vulvar pyoderma gangrenosum and Crohn's disease.
Borum ML; Cannava M; Myrie-Williams C
Dig Dis Sci; 1998 Apr; 43(4):720-2. PubMed ID: 9558025
[No Abstract] [Full Text] [Related]
16. Use of infliximab in pyoderma gangrenosum.
Hewitt D; Tait C
Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes.
Westerdahl JS; Nusbaum KB; Chung CG; Kaffenberger BH; Ortega-Loayza AG
J Dermatolog Treat; 2022 Jun; 33(4):2386-2390. PubMed ID: 34057010
[No Abstract] [Full Text] [Related]
18. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease.
Batres LA; Mamula P; Baldassano RN
J Pediatr Gastroenterol Nutr; 2002 May; 34(5):558-60. PubMed ID: 12050585
[No Abstract] [Full Text] [Related]
19. Dermatologic manifestations of Crohn disease in children: response to infliximab.
Kugathasan S; Miranda A; Nocton J; Drolet BA; Raasch C; Binion DG
J Pediatr Gastroenterol Nutr; 2003 Aug; 37(2):150-4. PubMed ID: 12883301
[TBL] [Abstract][Full Text] [Related]
20. Massive pyoderma gangrenosum in a 77 year old female with Crohn's disease responsive to adalimumab.
Lipka S; Katz S; Ginzburg L
J Crohns Colitis; 2013 Jun; 7(5):427-8. PubMed ID: 22926276
[No Abstract] [Full Text] [Related]
[Next] [New Search]
